Work for Trillium Therapeutics Inc.?

Claim Your Profile

Trillium Therapeutics Inc. Logo Image

Trillium Therapeutics Inc.

Trillium Therapeutics Inc. Banner Image

About Trillium Therapeutics Inc.

11-50 Employees
Based in Mississauga, Ontario

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. They have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat” signal with decoy receptors, they aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.

Ticker:
TRIL
Exchange:
TSX (See More TSX Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol